COVID-19-Related Antibodies

Recombinant mAbs for SARS-CoV-2 Research 

Monoclonal antibodies (mAbs) against SARS-CoV-2 antigens or host pro-inflammatory cytokine receptors are under therapeutic investigation for fighting COVID-19. InvivoGen offers isotype families of recombinant mAbs related to COVID-19 research.

• Anti-SARS-CoV-Spike mAbs (clone CR3022) - targets the SARS-CoV spike RBD 
• Anti-human IL-6 receptor (Tocilizumab-derived) - targets the human interleukin 6 receptor (hIL-6R)

ISOTYPE FAMILIES

These antibodies are available with different immunoglobulin isotypes, either native or engineered. The different isotypes can trigger or hinder mAb effector functions including, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Depending on your target and application, InvivoGen offers:

• Human isotypes

hIgG1: highly-represented in the serum and a potent inducer of ADCC and CDC
hIgG1NQ: non-glycosylated hIgG1 exhibiting ablated ADCC and severely compromised CDC
hIgA: main antibody isotype present in mucosal secretions (i.e. in the respiratory tract) and a moderate inducer of ADCC
hIgM: first antibody isotype raised in the immune response and a potent inducer of CDC

• Mouse isotypes

mIgG2a: most potent inducer of ADCC and CDC among murine isotypes
mIgG1e3: effectorless mIgG1 with a D265A point mutation

As a guarantee of quality, our antibody constructs are fully sequenced and their target binding has been validated.

InvivoGen’s products are for research use only, and not for clinical or veterinary use.

Learn more about SARS-CoV-2 infection cycle, immune responses, and potential therapeutics